Associate Professor of Surgery Harvard Medical School, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center Scituate, Massachusetts, United States
Advancements in the treatment of early breast cancer (EBC) are expanding potential to prevent recurrence and metastatic progression in this patient population. Therapeutic options are growing and diversifying across TNBC, HER2+, and HR+, HER2- subtypes, fueled by systemic therapy approvals, including immunotherapy, CDK4/6 and PARP inhibitors, and various HER2-targeted regimens. With still more promising therapies emerging from clinical trials, such as HER2- and TROP2-targeting antibody–drug conjugates and oral SERDs, it is essential for healthcare providers to stay ahead of the rapidly evolving evidence and guidelines to provide optimal care for patients.
Join our multidisciplinary panel of EBC experts in this PeerView live symposium for a clear, practical update on the latest data shaping modern standards of care and the key advances on the horizon for patients with TNBC, HER2+, and HR+, HER2- disease. Participants will gain guidance on interpreting the latest evidence, effectively collaborating and building better alliances among surgeons, oncologists, and other members of the multidisciplinary/interprofessional team, developing and implementing individualized, multimodal treatment plans, and proactively anticipating and managing treatment-related adverse events. Register today to sharpen your approach to modern EBC care!
Learning Objectives:
Analyze current and emerging clinical evidence for the use of established, novel, and investigational therapies in the management of EBC across various subtypes.
Apply best practices in patient evaluation, risk assessment, and biomarker testing to inform individualized treatment strategies for patients with EBC.
Implement team-based, patient-centric care plans that incorporate the latest systemic therapies for EBC to optimize efficacy and minimize adverse effects.
